Skip to main content

Reduced expression of ELAVL4 in male meningioma patients

Brain Tumor Pathology volume 30, pages 160–166 (2013)Cite this article

Abstract

Meningioma is a frequently occurring tumor of the central nervous system. Among many genetic alternations, the loss of the short arm of chromosome 1 is the second most frequent chromosomal abnormality observed in these tumors. Here, we focused on the previously described and well-established minimal deletion regions of chromosome 1. In accordance with the Knudson suppressor theory, we designed an analysis of putative suppressor genes localized in the described minimal deletion regions. The purpose was to determine the molecular background of the gender-specific occurrence of meningiomas. A total of 149 samples were examined for loss of heterozygosity (LOH). In addition, 57 tumor samples were analyzed using real-time polymerase chain reaction. We examined the association between the expression of selected genes and patient age, gender, tumor grade and presence of 1p loss. Furthermore, we performed an analysis of the most stable internal control for real-time analysis in meningiomas. LOH analysis revealed gender-specific discrepancies in the frequency of 1p aberrations. Moreover, statistical correlation between the gene expression level and gender was significant for the ELAVL4 gene as we found it to be lower in males than in females. We conclude that meningiomas present different features depending on patient gender. We suggest that ELAVL4 can be involved in the pathogenesis of meningiomas in male patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Collins VP (2004) Brain tumours classification and genes. J Neurol Neurosurg Psychiatry 75:ii2–ii11

    Google Scholar 

  2. Wozniak K, Piaskowski S, Gresner SM et al (2008) BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region. Cancer Genet Cytogenet 183:14–20

    PubMed  Article  CAS  Google Scholar 

  3. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489

    PubMed  CAS  Google Scholar 

  4. Imyanitov EN, Birrell GW, Filippovich I et al (1999) Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target. Oncogene 18:4640–4642

    PubMed  Article  CAS  Google Scholar 

  5. Lothe RA, Andersen SN, Hofstad B et al (1995) Deletion of 1p loci and microsatellite instability in colorectal polyps. Genes Chromosom Cancer 14:182–188

    PubMed  Article  CAS  Google Scholar 

  6. Bagchi A, Papazoglu C, Wu Y et al (2007) CHD5 is a tumor suppressor at human 1p36. Cell 128:459–475

    PubMed  Article  CAS  Google Scholar 

  7. Tabernero MD, Espinosa AB, Maillo A et al (2007) Patient gender is associated with distinct patterns of chromosomal abnormalities and sex chromosome linked gene-expression profiles in meningiomas. Oncologist 12:1225–1236

    PubMed  Article  CAS  Google Scholar 

  8. Lee Y, Liu J, Patel S et al (2010) Genomic landscape of meningiomas. Brain Pathol 20:751–762

    PubMed  Article  CAS  Google Scholar 

  9. Piaskowski S, Rieske P, Szybka M et al (2005) GADD45A and EPB41 as tumor suppressor genes in meningioma pathogenesis. Cancer Genet Cytogenet 162:63–67

    PubMed  Article  CAS  Google Scholar 

  10. Bièche I, Khodja A, Lidereau R (1999) Deletion mapping of chromosomal region 1p32-pter in primary breast cancer. Genes Chromosom Cancer 24:255–263

    PubMed  Article  Google Scholar 

  11. Millikan RC, Ingles SA, Diep AT et al (1999) Linkage analysis and loss of heterozygosity for chromosome arm 1p in familial breast cancer. Genes Chromosom Cancer 25:354–361

    PubMed  Article  CAS  Google Scholar 

  12. Ogunbiyi OA, Goodfellow PJ, Gagliardi G et al (1997) Prognostic value of chromosome 1p allelic loss in colon cancer. Gastroenterology 113:761–766

    PubMed  Article  CAS  Google Scholar 

  13. Aarts M, Dannenberg H, deLeeuw RJ et al (2006) Microarray-based CGH of sporadic and syndrome-related pheochromocytomas using a 0.1–0.2 Mb bacterial artificial chromosome array spanning chromosome arm 1p. Genes Chromosom Cancer 45:83–93

    PubMed  Article  CAS  Google Scholar 

  14. Grizzi F, Chiriva-Internati M (2006) Cancer: looking for simplicity and finding complexity. Cancer Cell Int 6:4

    PubMed  Article  Google Scholar 

  15. Gorringe KL, Choong DY, Williams LH et al (2008) Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 10:1253–1258

    PubMed  CAS  Google Scholar 

  16. Henrich KO, Fischer M, Mertens D et al (2006) Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin Cancer Res 12:131–138

    PubMed  Article  CAS  Google Scholar 

  17. Lou C, Du Z, Yang B et al (2009) Aberrant DNA methylation profile of hepatocellular carcinoma and surgically resected margin. Cancer Sci 100:996–1004

    PubMed  Article  CAS  Google Scholar 

  18. Kim HJ, Lotan R (2005) Identification of protein modulation by the synthetic retinoid CD437 in lung carcinoma cells using high throughput immunoblotting. Int J Oncol 26:483–491

    PubMed  CAS  Google Scholar 

  19. Bjørling-Poulsen M, Seitz G, Guerra B et al (2003) The pro-apoptotic FAS-associated factor 1 is specifically reduced in human gastric carcinomas. Int J Oncol 23:1015–1023

    PubMed  Google Scholar 

  20. Takeuchi T, Sasaki Y, Ueki T et al (1996) Modulation of growth and apoptosis response in PC-3 and LNCAP prostate-cancer cell lines by Fas. Int J Cancer 67:709–714

    PubMed  Article  CAS  Google Scholar 

  21. Guijarro MV, Leal JF, Fominaya J et al (2007) MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis 28:1646–1652

    PubMed  Article  CAS  Google Scholar 

  22. Louis DN, Ohgaki H, Wiestler OD et al (2007) The WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109

    PubMed  Article  Google Scholar 

  23. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36

    PubMed  Article  Google Scholar 

  24. geNorm program. Available at: http://medgen.ugent.be/~jvdesomp/genorm/

  25. BestKeeper program. Available at: http://www.gene-quantification.de/bestkeeper.html

  26. Barbashina V, Salazar P, Holland EC et al (2005) Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 11:1119–1128

    PubMed  CAS  Google Scholar 

  27. Schlisio S, Kenchappa RS, Vredeveld CW et al (2008) The kinesin KIF1Bβ acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 22:884–893

    PubMed  Article  CAS  Google Scholar 

  28. Okawa ER, Gotoh T, Manne J et al (2008) Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 27:803–810

    PubMed  Article  CAS  Google Scholar 

  29. Munirajan AK, Ando K, Mukai A et al (2008) KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death. J Biol Chem 283:24426–24434

    PubMed  Article  CAS  Google Scholar 

  30. Piao GH, Piao WH, He Y et al (2008) Hyper-methylation of RIZ1 tumor suppressor gene is involved in the early tumorigenesis of hepatocellular carcinoma Cancer. Epidemiol Biomarkers Prev 17:3567–3572

    Article  Google Scholar 

  31. Gutmann DH, Hirbe AC, Huang ZY et al (2001) The protein 4.1 tumor suppressor, DAL-1, impairs cell motility, but regulates proliferation in a cell-type-specific fashion. Neurobiol Dis 8:266–278

    PubMed  Article  CAS  Google Scholar 

  32. Robb VA, Li W, Gascard P et al (2003) Identification of a third protein 4.1 tumor suppressor, protein 4.1R, in meningioma pathogenesis. Neurobiol Dis 13:191–202

    PubMed  Article  CAS  Google Scholar 

  33. Malaguarnera R, Vella V, Pandini G et al (2008) TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation. Mol Cancer Res 6:64–67

    PubMed  Article  CAS  Google Scholar 

  34. Huang S, Lichtenauer UD, Pack S et al (2001) Reassignment of the EPB4.1 gene to 1p36 and assessment of its involvement in neuroblastomas. Eur J Clin Invest 31:907–914

    PubMed  Article  CAS  Google Scholar 

  35. Jiang GL, Huang S (2000) The yin-yang of PR-domain family genes in tumorigenesis. Histol Histopathol 15:109–117

    PubMed  CAS  Google Scholar 

  36. Kim KC, Geng L, Huang S (2003) Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res 63:7619–7623

    PubMed  CAS  Google Scholar 

  37. Stiewe T, Putzer BM (2002) Role of p73 in malignancy: tumor suppressor or oncogene. Cell Death Differ 9:237–245

    PubMed  Article  CAS  Google Scholar 

  38. Marabese M, Marchini S, Sabatino MA et al (2005) Effects of inducible overexpression of DNp73alpha on cancer cell growth and response to treatment in vitro and in vivo. Cell Death Differ 12:805–814

    PubMed  Article  CAS  Google Scholar 

  39. Liu SS, Chan KY, Cheung AN et al (2006) Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res 12:3922–3927

    PubMed  Article  CAS  Google Scholar 

  40. Melino G, Lu X, Gasco M et al (2003) Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 28:663–670

    PubMed  Article  CAS  Google Scholar 

  41. Lomas J, Amiñoso C, Gonzalez-Gomez P et al (2004) Methylation status of TP73 in meningiomas. Cancer Genet Cytogenet 148:148–151

    PubMed  Article  CAS  Google Scholar 

  42. Moll UM, Slade N (2004) p63 and p73: roles in development and tumor formation. Mol Cancer Res 2:371–386

    PubMed  CAS  Google Scholar 

  43. Nakane Y, Natsume A, Wakabayashi T et al (2007) Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1AJ. Neurosurgery 107:398–404

    Article  CAS  Google Scholar 

  44. Leone PE, Walker BA, Jenner MW et al (2008) Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res 14:6033–6041

    PubMed  Article  CAS  Google Scholar 

  45. Boström J, Meyer-Puttlitz B, Wolter M et al (2001) Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 159:661–669

    PubMed  Article  Google Scholar 

  46. Kirsch M, Mörz M, Pinzer T et al (2009) Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas. Genes Chromosom Cancer 48:143–154

    PubMed  Article  CAS  Google Scholar 

  47. Iolascon A, Giordani L, Moretti A et al (1998) Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma. Hepatology 27:989–995

    PubMed  Article  CAS  Google Scholar 

  48. Iolascon A, Giordani L, Moretti A et al (1998) Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma. Pediatr Res 43:139–144

    PubMed  Article  CAS  Google Scholar 

  49. Blanquicett C, Johnson MR, Heslin M et al (2002) Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Anal Biochem 303:209–214

    PubMed  Article  CAS  Google Scholar 

  50. Radonic A, Thulke S, Mackay IM et al (2004) Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 313:856–862

    PubMed  Article  CAS  Google Scholar 

  51. Antic D, Keene JD (1997) Embryonic lethal abnormal visual RNA-binding proteins involved in growth, differentiation, and posttranscriptional gene expression. Am J Hum Genet 61:273–278

    PubMed  Article  CAS  Google Scholar 

  52. Tanner DC, Qiu S, Bolognani F et al (2008) Alterations in mossy fiber physiology and GAP-43 expression and function in transgenic mice overexpressing HuD. Hippocampus 18:814–823

    PubMed  Article  CAS  Google Scholar 

  53. Akamatsu W, Fujihara H, Mitsuhashi T et al (2005) The RNA-binding protein HuD regulates neuronal cell identity and maturation. PNAS 102:4625–4630

    PubMed  Article  CAS  Google Scholar 

  54. D’Alessandro V, Muscarella LA, la Torre A et al (2010) Molecular analysis of the HuD gene in neuroendocrine lung cancers. Lung Cancer 67:69–75

    PubMed  Article  Google Scholar 

  55. Choi KJ, Lee JH, Kim KS et al (2011) Identification of ELAVL4 as a modulator of radiation sensitivity in A549 non-small cell lung cancer cells. Oncol Rep 26:55–63

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was partially sponsored by the Polpharma Science Foundation.

Author information

Affiliations

  1. Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Czechoslowacka 8/10, 92-216, Lodz, Poland

    Robert Stawski, Sylwester Piaskowski, Ewelina Stoczynska-Fidelus, Krystyna Wozniak, Michal Bienkowski, Magdalena Zakrzewska, Monika Witusik-Perkowska, Beata Sikorska, Piotr Rieske & Pawel P. Liberski

  2. Department of Neurosurgery, Medical University of Lodz, Kopcinskiego 22, 90-153, Lodz, Poland

    Dariusz J. Jaskolski

  3. Department of Neurosurgery, WSS Olsztyn, Zolnierska 18, 10-561, Olsztyn, Poland

    Waldemar Och

  4. Chair of Pathology, Medical University of Lodz, Czechoslowacka 8/10, 92-216, Lodz, Poland

    Wielislaw Papierz

Authors
  1. Robert Stawski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sylwester Piaskowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ewelina Stoczynska-Fidelus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Krystyna Wozniak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michal Bienkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Magdalena Zakrzewska
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Monika Witusik-Perkowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dariusz J. Jaskolski
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Waldemar Och
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wielislaw Papierz
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Beata Sikorska
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Piotr Rieske
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Pawel P. Liberski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sylwester Piaskowski.

Additional information

R. Stawski and S. Piaskowski contributed equally to this work.

About this article

Cite this article

Stawski, R., Piaskowski, S., Stoczynska-Fidelus, E. et al. Reduced expression of ELAVL4 in male meningioma patients. Brain Tumor Pathol 30, 160–166 (2013). https://doi.org/10.1007/s10014-012-0117-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10014-012-0117-x

Keywords

  • Tumor suppressor gene
  • Meningiomas
  • Internal control
  • HuD
  • ELAVL4